Skip to main content
. 2017 Nov 24;7:16231. doi: 10.1038/s41598-017-13431-y

Figure 1.

Figure 1

MK increases the survival of cisplatin-treated tumour cells in vitro. The effect of cisplatin on tumour cells with MK pretreatment was determined by means of cell viability assays via a CCK-8 kit (*P < 0.05, **P < 0.01, ***P < 0.001). HSC3 (a), OSCC3 (b), SCC4 (c), A549 (d) and SKOV3 (e) cells were treated with exogenous MK (100 ng/mL) for the indicated time before treatment with the corresponding concentrations of cisplatin (HSC3 6 µM, OSCC3 5 µM, SCC4 9 µM, A549 4.6 µM, and SKOV3 12 µM) for 48 h. Data are representative of three independent experiments.